Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia

Drug Discovery Today: Technologies

Volumn 11, Issue 1, 2014, Pages 89-99

  Balabanov, Stefan ^a   Braig, Melanie ^a   Brümmendorf, Tim H ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; HOMOHARRINGTONINE; IMATINIB; ISOLEUCINE; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; ORGANIC CATION TRANSPORTER 1; PHOSPHATIDYLINOSITOL 3 KINASE; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; THREONINE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; DISEASE COURSE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME CONFORMATION; HUMAN; HYDROGEN BOND; IC 50; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA REMISSION; MUTAGENESIS; MUTATION; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; DRUG RESISTANCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS;

EID: 84899966445     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2014.03.003     Document Type: Review

References (94)

1. R. Virchow Weisses Blut Frorieps Notizen 36 1845 151 156
2. J.H. Bennett Case of hypertrophy of the spleen and liver in which death took place from the suppuration of the blood Edinburgh Med Surg J 64 1845 413 423
3. J.M. Goldman Chronic myeloid leukemia: a historical perspective Semin Hematol 47 2010 302 311
4. P.C. Nowell, and D.A. Hungerford A minute chromosome in human chronic granulocytic leukemia Science 132 1960
5. J.D. Rowley Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 1973 290 293
6. C.R. Bartram et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia Nature 306 1983 277 280
7. J. Groffen et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 Cell 36 1984 93 99
8. B.J. Druker et al. Chronic myelogenous leukemia ASH Education Program Book 2001 2001 87 112
9. G.Q. Daley et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 247 1990 824 830
10. B.J. Druker et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
11. B.J. Druker et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
12. S.G. O'Brien et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
13. B.J. Druker et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
14. A. Hochhaus et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 2009 1054 1061
15. J.F. Apperley Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 8 2007 1018 1029
16. E. Weisberg et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141
17. M. Talpaz et al. Dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias N Engl J Med 354 2006 2531 2541
18. N.P. Shah et al. Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401
19. J.E. Cortes et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial J Clin Oncol 30 2012 3486 3492
20. H.M. Kantarjian et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors Blood 2013
21. T. O'Hare et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 16 2009 401 412
22. J. Cortes et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood 110 2007 4005 4011
23. O. Hantschel, and G. Superti-Furga Regulation of the c-Abl and Bcr-Abl tyrosine kinases Nat Rev Mol Cell Biol 5 2004 33 44
24. E.P. Reddy, and A.K. Aggarwal The ins and outs of bcr-abl inhibition Genes Cancer 3 5-6 2012 447 454
25. J. Zimmermann et al. Potent and selective inhibitors of the Abl-kinase: phenylaminopyrimidine (PAP) derivatives Bioorg Med Chem Lett 7 2 1997 187 192
26. T. Schindler et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase Science 289 5486 2000 1938 1942
27. N. Vajpai et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by nmr substantiate the different binding modes of imatinib/nilotinib and dasatinib J Biol Chem 283 26 2008 18292 18302
28. M.J. Eck, and P.W. Manley The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl Curr Opin Cell Biol 21 2 2009 288 295
29. L. Skora et al. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors Proc Natl Acad Sci 110 47 2013 E4437 E4445
30. P.W. Manley et al. Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases Bioorg Med Chem Lett 14 23 2004 5793 5797
31. P.W. Manley et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib Bioorg Med Chem 18 19 2010 6977 6986
32. J.S. Tokarski et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Res 66 11 2006 5790 5797
33. N.M. Levinson, and S.G. Boxer Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain PLoS ONE 7 4 2012 e29828
34. N.M. Levinson, and S.G. Boxer A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity Nat Chem Biol 2013 advance online publication
35. J.E. Cortes et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias N Engl J Med 367 22 2012 2075 2088
36. W-S. Huang et al. Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl) ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl) phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant J Med Chem 53 12 2010 4701 4719
37. T. Anastassiadis et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat Biotech 29 11 2011 1039 1045
38. M.I. Davis et al. Comprehensive analysis of kinase inhibitor selectivity Nat Biotech 29 11 2011 1046 1051
39. U. Rix et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood 110 12 2007 4055 4063
40. M. Bantscheff et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat Biotech 25 9 2007 1035 1044
41. F.A.B. Schutz et al. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors J Clin Oncol 30 8 2012 871 877
42. S. Balabanov et al. Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors PLoS ONE 8 1 2013 e53668
43. H. Emir et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML Blood 122 21 2013 257
44. M. Baccarani et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia Blood 122 6 2013 872 884
45. T.P. Hughes et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib Blood 2013
46. M.E. Gorre et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 5531 2001 876 880
47. E. Jabbour et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate Leukemia 20 10 2006 1767 1773
48. J.M. Diamond, and J.V. Melo Mechanisms of resistance to BCR-ABL kinase inhibitors Leuk Lymphoma 52 Suppl 1 2011 12 22
49. M. Azam et al. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL Cell 112 6 2003 831 843
50. D.W. Sherbenou et al. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib Blood 116 17 2010 3278 3285
51. N.P. Shah et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency J Clin Invest 117 9 2007 2562 2569
52. J.S. Khorashad et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships Blood 121 3 2013 489 498
53. S. Soverini et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors Blood 114 10 2009 2168 2171
54. T. Hughes et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase J Clin Oncol 27 25 2009 4204 4210
55. F.X. Mahon et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression Cancer Res 68 23 2008 9809 9816
56. P. le Coutre et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 95 5 2000 1758 1766
57. D.J. Barnes et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia Cancer Res 65 19 2005 8912 8919
58. A. Hamilton et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival Blood 119 6 2012 1501 1510
59. A.S. Corbin et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity J Clin Investig 121 1 2011 396 409
60. S. Picard et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood 109 8 2007 3496 3499
61. B. Peng et al. Clinical pharmacokinetics of imatinib Clin Pharmacokinet 44 9 2005 879 894
62. Iurlo, A. et al. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. Eur J Intern Med
63. A. Haouala et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib Blood 117 8 2011 e75 e87
64. A.R. Ibrahim et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy Blood 117 14 2011 3733 3736
65. D. Marin et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib J Clin Oncol 28 14 2010 2381 2388
66. K. Eechoute et al. Drug transporters and imatinib treatment: implications for clinical practice Clin Cancer Res 17 3 2011 406 415
67. N.E. Jordanides et al. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate Blood 108 4 2006 1370 1373
68. S. Balabanov et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro PLoS ONE 6 4 2011 e19164
69. A. Gontarewicz, and T.H. Brummendorf Danusertib (formerly PHA-739358) - a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor Recent Results Cancer Res 184 2010 199 214
70. S.G. Willis et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Blood 106 6 2005 2128 2137
71. S. Angelini et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy Haematologica 98 2 2013 193 200
72. D.L. White et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib Haematologica 97 6 2012 907 914
73. D.K. Hiwase et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications Clin Cancer Res 14 12 2008 3881 3888
74. A. Burchert et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development Leukemia 19 10 2005 1774 1782
75. T. Pene-Dumitrescu, and T.E. Smithgall Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner J Biol Chem 285 28 2010 21446 21457
76. J. Wu et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase J Natl Cancer Inst 100 13 2008 926 939
77. P.C. Nowell The clonal evolution of tumor cell populations Science 194 4260 1976 23 28
78. S. Soverini et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain Blood 122 9 2013 1634 1648
79. B. Werner et al. Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data PLoS ONE 6 12 2011 e28955
80. B. Hanfstein et al. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy Haematologica 96 3 2011 360 366
81. N. Komarova Stochastic modeling of drug resistance in cancer J Theor Biol 239 3 2006 351 366
82. Z. Iqbal et al. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era PLoS ONE 8 2 2013 e55717
83. R. Hehlmann et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia J Clin Oncol 29 12 2011 1634 1642
84. M. Baccarani et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study Blood 113 19 2009 4497 4504
85. H. Kantarjian et al. Nilotinib in imatinib-resistant CML and Philadelphia Chromosome Positive ALL N Engl J Med 354 24 2006 2542 2551
86. H.J. Khoury et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure Blood 119 15 2012 3403 3412
87. G. Saglio et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 24 2010 2251 2259
88. H. Kantarjian et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 24 2010 2260 2270
89. F.P. Santos et al. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia Curr Opin Investig Drugs 11 12 2010 1450 1465
90. C.A. Eide et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile Cancer Res 71 9 2011 3189 3195
91. A.Q. Hassan et al. Allosteric inhibition of BCR-ABL Cell Cycle 9 18 2010 3710 3714
92. S. Lu, and J. Wang Homoharringtonine and omacetaxine for myeloid hematological malignancies J Hematol Oncol 7 1 2014 2
93. T. O'Hare et al. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 110 7 2007 2242 2249
94. S. Redaelli et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors Am J Hematol 87 11 2012 E125 E128